Study supports use of LMWH over warfarin for treatment of acute VTE in patients with active cancer
the ONA take:
The use of the low molecular-weight heparin (LMWH) tinzaparin daily for 6 months compared with warfarin was associated with a lower rate of clinically relevant nonmajor bleeding among patients with active cancer and acute symptomatic venous thromboembolism (VTE), according to a new study published in JAMA; however, there was no significant difference in reducing recurrent VTE, overall death, or major bleeding.
Previous data has shown that LMWH is preferred over warfarin for the treatment of acute VTE in patients with active cancer, but that recommendation is largely based on results of a single trial. Therefore, researchers sought to compare the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic VTE in patients with active cancer.
For the study, researchers enrolled 900 adult patients with active cancer from 164 centers in 5 continents and randomly assigned them 1:1 to receive tinzaparin 175 IU/kg once daily for 6 months vs conventional therapy with tinzaparin 175 IU/kg once daily for 5 to 10 days followed by warfarin dose-adjusted to an INR of 2.0-3.0 for 6 months.
The findings suggest that further studies are warranted to evaluate efficacy outcomes among patients with active cancer at higher risk for recurrent VTE.
Use of low molecular-weight heparin (LMWH) tinzaparin daily associated with lower rate of bleeding among patients with active cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|